The Experts below are selected from a list of 603 Experts worldwide ranked by ideXlab platform
Ziva Rosenthalgalili - One of the best experts on this subject based on the ideXlab platform.
-
the fatty Acid Bile Acid Conjugate aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease
Clinical Gastroenterology and Hepatology, 2014Co-Authors: Rifaat Safadi, Fred M Konikoff, Mahmud Mahamid, Shira Zelbersagi, Maya Halpern, Tuvia Gilat, Ran Oren, Alice Hershkovitz, Ziva RosenthalgaliliAbstract:CONCLUSIONS: Three months’ administration of the fatty Acid–Bile Acid Conjugate Aramchol is safe, tolerable, and significantly reduces liver fat content in patients with NAFLD. The reduction in liver fat content occurred in a dose-dependent manner and was associated with a trend of metabolic improvements, indicating that Aramchol might be used for the treatment of fatty liver disease. ClinicalTrials.gov number: NCT01094158.
Shira Zelbersagi - One of the best experts on this subject based on the ideXlab platform.
-
the fatty Acid Bile Acid Conjugate aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease
Clinical Gastroenterology and Hepatology, 2014Co-Authors: Rifaat Safadi, Fred M Konikoff, Mahmud Mahamid, Shira Zelbersagi, Maya Halpern, Tuvia Gilat, Ran Oren, Alice Hershkovitz, Ziva RosenthalgaliliAbstract:CONCLUSIONS: Three months’ administration of the fatty Acid–Bile Acid Conjugate Aramchol is safe, tolerable, and significantly reduces liver fat content in patients with NAFLD. The reduction in liver fat content occurred in a dose-dependent manner and was associated with a trend of metabolic improvements, indicating that Aramchol might be used for the treatment of fatty liver disease. ClinicalTrials.gov number: NCT01094158.
Rifaat Safadi - One of the best experts on this subject based on the ideXlab platform.
-
the fatty Acid Bile Acid Conjugate aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease
Clinical Gastroenterology and Hepatology, 2014Co-Authors: Rifaat Safadi, Fred M Konikoff, Mahmud Mahamid, Shira Zelbersagi, Maya Halpern, Tuvia Gilat, Ran Oren, Alice Hershkovitz, Ziva RosenthalgaliliAbstract:CONCLUSIONS: Three months’ administration of the fatty Acid–Bile Acid Conjugate Aramchol is safe, tolerable, and significantly reduces liver fat content in patients with NAFLD. The reduction in liver fat content occurred in a dose-dependent manner and was associated with a trend of metabolic improvements, indicating that Aramchol might be used for the treatment of fatty liver disease. ClinicalTrials.gov number: NCT01094158.
Henriette Molinari - One of the best experts on this subject based on the ideXlab platform.
-
solution structure of the supramolecular adduct between a liver cytosolic Bile Acid binding protein and a Bile Acid based gadolinium iii chelate a potential hepatospecific magnetic resonance imaging contrast agent
Journal of Medicinal Chemistry, 2008Co-Authors: Simona Tomaselli, Serena Zanzoni, Laura Ragona, Eliana Gianolio, Silvio Aime, Michael Assfalg, Henriette MolinariAbstract:Bile Acid-Conjugated gadolinium chelates were shown to display promising features for the development of hepatospecific constrast agents for magnetic resonance imaging (MRI). The study of the pharmacokinetics of these compounds should address their possible interaction with the Bile Acid protein transporters. We have previously shown that a 5beta-cholanoic Acid-based contrast agent is efficiently internalized in hepatocytes and is able to bind to a liver Bile Acid binding protein (BABP) in vitro. Here we report the solution structure of the adduct between a BABP and a gadolinium chelate/Bile Acid Conjugate. The identification of unambiguous intermolecular distance restraints was possible through 3D edited/filtered NOESY-HSQC experiments, together with distance information derived from paramagnetic relaxation enhancements. These intermolecular contacts were used for the structure determination of the complex, using the data-driven docking software HADDOCK. The obtained results represent the starting point for the design of new and more efficient MRI contrast agents.
Lorenzo Romeroramirez - One of the best experts on this subject based on the ideXlab platform.
-
tgfβ contributes to the anti inflammatory effects of tauroursodeoxycholic Acid on an animal model of acute neuroinflammation
Molecular Neurobiology, 2017Co-Authors: Natalia Yanguascasas, Asuncion M Barredamanso, Manuel Nietosampedro, Sandra Perezrial, Lorenzo RomeroramirezAbstract:The Bile Acid Conjugate tauroursodeoxycholic Acid (TUDCA) is a neuroprotective agent in various animal models of neuropathologies. We have previously shown the anti-inflammatory properties of TUDCA in an animal model of acute neuroinflammation. Here, we present a new anti-inflammatory mechanism of TUDCA through the regulation of transforming growth factor β (TGFβ) pathway. The bacterial lipopolysaccharide (LPS) was injected intravenously (iv) on TGFβ reporter mice (Smad-binding element (SBE)/Tk-Luc) to study in their brains the real-time activation profile of the TGFβ pathway in a non-invasive way. The activation of the TGFβ pathway in the brain of SBE/Tk-Luc mice increased 24 h after LPS injection, compared to control animals. This activation peak increased further in mice treated with both LPS and TUDCA than in mice treated with LPS only. The enhanced TGFβ activation in mice treated with LPS and TUDCA correlated with both an increase in TGFβ3 transcript in mouse brain and an increase in TGFβ3 immunoreactivity in microglia/macrophages, endothelial cells, and neurons. Inhibition of the TGFβ receptor with SB431542 drug reverted the effect of TUDCA on microglia/macrophages activation and on TGFβ3 immunoreactivity. Under inflammatory conditions, treatment with TUDCA enhanced further the activation of TGFβ pathway in mouse brain and increased the expression of TGFβ3. Therefore, the induction of TGFβ3 by TUDCA might act as a positive feedback, increasing the initial activation of the TGFβ pathway by the inflammatory stimulus. Our findings provide proof-of-concept that TGFβ contributes to the anti-inflammatory effect of TUDCA under neuroinflammatory conditions.
-
tauroursodeoxycholic Acid reduces glial cell activation in an animal model of acute neuroinflammation
Journal of Neuroinflammation, 2014Co-Authors: Natalia Yanguascasas, Asuncion M Barredamanso, Manuel Nietosampedro, Lorenzo RomeroramirezAbstract:Background Bile Acids are steroid Acids found predominantly in the Bile of mammals. The Bile Acid Conjugate tauroursodeoxycholic Acid (TUDCA) is a neuroprotective agent in different animal models of stroke and neurological diseases. However, the anti-inflammatory properties of TUDCA in the central nervous system (CNS) remain unknown.